Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Key Markers of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia

27 Jun 2016

Abstract excerpt

The aim of this study was to identify key markers of minimal residual disease (MRD) in childhood Acute Lymphoblastic Leukemia (ALL). Bone marrow samples were collected at presentation from 139 patients with newly diagnosed B-lineage ALL. On the basis of the expression of CD19, CD10, and CD34 antigens by bone marrow cells, combined with the terminal deoxynucleotide transferase (TdT), CD38, CD45, CD58, CD21, CD66c,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27438018
DOI: 10.1097/mph.0000000000000624

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Key Markers of Minimal Residual Disease in Childhood Acute Lymphoblastic LeukemiaPMID 27438018Read ↗

New markers for minimal residual disease detection in acute lymphoblastic leukemiaSemantic proximity Read ↗

Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologiesSemantic proximity Read ↗

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical AdvancesSemantic proximity Read ↗

Detection of minimal residual disease in pediatric acute lymphoblastic leukemiaSemantic proximity Read ↗

Clinical utility of next‐generation sequencing‐based minimal residual disease in paediatric B‐cell acute lymphoblastic leukaemiaSemantic proximity Read ↗

Minimal Residual Disease Detection in Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Presence of minimal residual disease determined by next-generation sequencing is not a reliable prognostic biomarker in children with acute lymphoblastic leukemiaSemantic proximity Read ↗

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocolSemantic proximity Read ↗

Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patientSemantic proximity Read ↗

Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed TherapySemantic proximity Read ↗

Detection and management of minimal residual disease in acute lymphoblastic leukemiaSemantic proximity Read ↗

Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.